MELBOURNE, AUSTRALIA--(MARKET WIRE)--Aug 14, 2007 -- Prana Biotechnology Limited (NasdaqCM:PRAN - News) (ASX:PBT.AX - News), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, announced that reporting in today's edition of the journal, Proceedings of the National Academy of Sciences, the multi-institutional team led by Professor David Lynn showed how interactions between beta-amyloid (Abeta) and the biological metals copper and zinc can induce conformational alterations to the Abeta protein causing it to adopt a multitude of toxic forms.
